AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces that the company is participating in the Nordic Life Science Days event in Malmö, Sweden, and will hold a company presentation on Thursday, September 29, 2022, at 10:00 a.m.
CEO Jonas Jönmark will present AcuCort and summarize where the company stands in the commercialization process of the drug ISICORT®/Zeqmelit.
AcuCort will also participate in the partnering event to meet potential partners regarding out-licensing. The overarching goal for ISICORT®/Zeqmelit is to be commercialized globally, i.e. in the EU, US and selected key markets.
In the development of ISICORT®/Zeqmelit, AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions. The drug was recently approved in Denmark under the name Zeqmelit and has previously been approved in Sweden under the brand name ISICORT®.
For information about NLSDays.
The information was submitted for publication, through the agency of the contact person below, on September 22, 2022.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
About AcuCort AB (publ)
AcuCort has developed and commercializes ISICORT®/Zeqmelit, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. The product is approved in Sweden and Denmark. Altogether, this strengthens the company’s assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.se.